# A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma

> **NCT05912244** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** IO102/IO103
- **DRUG:** Nivolumab-Relatlimab

## Key facts

- **NCT ID:** NCT05912244
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-09
- **Primary completion:** 2027-06-09
- **Final completion:** 2027-06-09
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- IO Biotech

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05912244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05912244, "A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05912244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*